Physician profile
John G Gelinas
NPI 1841379534
$363,988.74
in general payments reported to CMS, 2019-2025
30 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $14K · 2021: $53K · 2022: $44K · 2023: $92K · 2024: $48K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $154K · Consulting Fee: $26K · Travel and Lodging: $19K · Honoraria: $16K · Food and Beverage: $10K · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,279.00 |
| Consulting Fee | $25,735.00 |
| Travel and Lodging | $19,491.59 |
| Honoraria | $16,050.00 |
| Food and Beverage | $10,356.31 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $86,303.44 | 2019-2025 | Ingrezza |
| Abbvie INC. | $79,789.77 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $55,966.88 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42,985.86 | 2022-2025 | Caplyta |
| Tris Pharma INC | $25,923.16 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $24,991.19 | 2022-2025 | Azstarys, Azstarys |
| Allergan, INC. | $23,491.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13,781.51 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $3,958.42 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $3,526.90 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $511.37 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Mycite |
| Alkermes, INC. | $498.78 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $459.63 | 2019-2025 | Rexulti, Brintellix |
| Teva Pharmaceuticals USA, INC. | $352.18 | 2019-2025 | Uzedy |
| Ironshore Pharmaceuticals INC. | $346.30 | 2019-2024 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $263.21 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $110.13 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $91.12 | 2019-2022 | |
| Bausch Health US, LLC | $82.20 | 2021-2023 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $79.73 | 2020-2025 | Relexxii |
| Janssen Scientific Affairs, LLC | $72.12 | 2019 | |
| Eisai INC. | $66.41 | 2021-2022 | |
| Rhodes Pharmaceuticals L.P. | $65.43 | 2019 | |
| Collegium Pharmaceutical, INC. | $57.90 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $50.79 | 2020 | |
| Neos Therapeutics, Lp | $50.41 | 2019-2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $46.92 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $24.93 | 2021 | |
| Avion Pharmaceuticals | $23.54 | 2023 | Methylphenidate Hydrochloride |
| Almatica Pharma LLC | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gelinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.